E-LIB Suche - Ergebnisse für: GREGORY, ALYSE

1

Phase II trial of fulvestrant plus enzalutamide in ER+/HER2..:

Elias, Anthony D. ; Spoelstra, Nicole S. ; Staley, Alyse W....
npj Breast Cancer. 9 (2023) 1 - p. , 2023

2

Phase II trial of fulvestrant plus enzalutamide in ER+/HER2..:

Elias, Anthony D ; Spoelstra, Nicole S ; Staley, Alyse W...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199936/. , 2023

Link: http://www.ncbi.nlm.nih...

3

Phase II trial of fulvestrant plus enzalutamide in ER+/HER2..:

Anthony D. Elias ; Nicole S. Spoelstra ; Alyse W. Staley...
https://doi.org/10.1038/s41523-023-00544-z. , 2023

Link: https://doi.org/10.1038/..

4

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373..:

Tian, Jing-Hui ; Patel, Nita ; Haupt, Robert...
Nature Communications. 12 (2021) 1 - p. , 2021

Link: https://doi.org/10.1038/..

5

[Letters and report from the Western Gazette]:

POWYS, LLEWELYN ; GREGORY, ALYSE ; POWYS, G.M....
The Powys Journal. 31 (2021) - p. 119-122 , 2021

Link: https://www.jstor.org/st..

6

Fab and Fc contribute to maximal protection against SARS-Co..:

Gorman, Matthew J. ; Patel, Nita ; Guebre-Xabier, Mimi...
Cell Reports Medicine. 2 (2021) 9 - p. 100405 , 2021

Link: https://doi.org/10.1016/..

7

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373..:

Jing-Hui Tian ; Nita Patel ; Robert Haupt...
https://doi.org/10.1038/s41467-020-20653-8. , 2021

Link: https://doi.org/10.1038/..

8

Fab and Fc contribute to maximal protection against SARS-Co..:

Gorman, Matthew J ; Patel, Nita ; Guebre-Xabier, Mimi...
Cell Reports. Medicine. , 2021

Link: http://hdl.handle.net/10..

9

Collaboration between the Fab and Fc contribute to maximal ..:

Gorman, Matthew J ; Patel, Nita ; Guebre-Xabier, Mimi...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872351/. , 2021

Link: http://www.ncbi.nlm.nih...

10

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373..:

Tian, Jing-Hui ; Patel, Nita ; Haupt, Robert...
Nature Communications. , 2021

Link: http://hdl.handle.net/10..

11

Fab and Fc contribute to maximal protection against SARS-Co..:

Matthew J. Gorman ; Nita Patel ; Mimi Guebre-Xabier...
http://www.sciencedirect.com/science/article/pii/S2666379121002639. , 2021

Link: https://doi.org/10.1016/..

12

Managing work flow in high enrolling trials: The developmen..:

David Pogorzelski ; Uyen Nguyen ; Paula McKay...
http://www.sciencedirect.com/science/article/pii/S2451865421000326. , 2021

Link: https://doi.org/10.1016/..

13

Patient and stakeholder engagement learnings: PREP-IT as a ..:

Medeiros, Michelle ; Love, T Rosie ; Slobogean, Gerard P...
10.2217/cer-2020-0266. , 2021

Link: https://hdl.handle.net/1..

14

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373..:

Tian, Jing-Hui ; Patel, Nita ; Haupt, Robert...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809486/. , 2021

Link: http://www.ncbi.nlm.nih...

15

Collaboration between the Fab and Fc contribute to maximal ..:

Alter, Galit ; Gorman, Matthew ; Patel, Nita...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899467/. , 2021

Link: http://www.ncbi.nlm.nih...